A 12-month observational study on the safety, efficacy on migraine-associated symptoms and satisfaction of CGRP monoclonal antibodies in Japanese patients with migraineShungo Imai, Tsubasa Takizawa, Narumi Watanabe et al.|Journal of the Neurological Sciences|2026Cited by 7
Reply: Pathophysiological, methodological, and statistical considerations in CGRP monoclonal antibody therapy: A comment on Imai et alShungo Imai, Tsubasa Takizawa, Keiko Ihara et al.|Journal of the Neurological Sciences|2026Cited by 1